Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

892 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity.
Caron NS, Haqqani AS, Sandhu A, Aly AE, Findlay Black H, Bone JN, McBride JL, Abulrob A, Stanimirovic D, Leavitt BR, Hayden MR. Caron NS, et al. Among authors: hayden mr. Brain Commun. 2022 Nov 25;4(6):fcac309. doi: 10.1093/braincomms/fcac309. eCollection 2022. Brain Commun. 2022. PMID: 36523269 Free PMC article.
Huntingtin Decreases Susceptibility to a Spontaneous Seizure Disorder in FVN/B Mice.
Van Raamsdonk JM, Al-Shekaili HH, Wagner L, Bredy TW, Chan L, Pearson J, Schwab C, Murphy Z, Devon RS, Lu G, Kobor MS, Hayden MR, Leavitt BR. Van Raamsdonk JM, et al. Among authors: hayden mr. Aging Dis. 2023 Dec 1;14(6):2249-2266. doi: 10.14336/AD.2023.0423. Aging Dis. 2023. PMID: 37199581 Free PMC article.
Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.
Caron NS, Aly AE, Findlay Black H, Martin DDO, Schmidt ME, Ko S, Anderson C, Harvey EM, Casal LL, Anderson LM, Rahavi SMR, Reid GSD, Oda MN, Stanimirovic D, Abulrob A, McBride JL, Leavitt BR, Hayden MR. Caron NS, et al. Among authors: hayden mr. J Control Release. 2024 Mar;367:27-44. doi: 10.1016/j.jconrel.2024.01.011. Epub 2024 Jan 24. J Control Release. 2024. PMID: 38215984 Free article.
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Schubert R, Loupe P, Wickenberg A, Borowsky B, Rynkowski G, Volkinshtein R, Li T, Savola JM, Hayden M, Gordon MF; LEGATO-HD Study Group. Reilmann R, et al. Lancet Neurol. 2024 Mar;23(3):243-255. doi: 10.1016/S1474-4422(23)00454-4. Epub 2024 Jan 24. Lancet Neurol. 2024. PMID: 38280392 Clinical Trial.
Allele-specific quantitation of ATXN3 and HTT transcripts in polyQ disease models.
Joachimiak P, Ciesiołka A, Kozłowska E, Świtoński PM, Figura G, Ciołak A, Adamek G, Surdyka M, Kalinowska-Pośka Ż, Figiel M, Caron NS, Hayden MR, Fiszer A. Joachimiak P, et al. Among authors: hayden mr. BMC Biol. 2023 Feb 1;21(1):17. doi: 10.1186/s12915-023-01515-3. BMC Biol. 2023. PMID: 36726088 Free PMC article.
Corrigendum to "Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease" [Neurobiology of Disease, 2024 Jan:190:106376].
Bartl S, Xie Y, Potluri N, Kesineni R, Hencak K, Cengio LD, Balazs K, Oueslati A, Parth M, Salhat N, Siddu A, Smrzka O, Cicchetti F, Staffler G, Hayden MR, Southwell AL. Bartl S, et al. Among authors: hayden mr. Neurobiol Dis. 2024 Apr;193:106444. doi: 10.1016/j.nbd.2024.106444. Epub 2024 Feb 24. Neurobiol Dis. 2024. PMID: 38402018 Free article. No abstract available.
892 results